Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Sensory cortical control of movement.

Karadimas SK, Satkunendrarajah K, Laliberte AM, Ringuette D, Weisspapir I, Li L, Gosgnach S, Fehlings MG.

Nat Neurosci. 2020 Jan;23(1):75-84. doi: 10.1038/s41593-019-0536-7. Epub 2019 Nov 18.

PMID:
31740813
2.

Cervical excitatory neurons sustain breathing after spinal cord injury.

Satkunendrarajah K, Karadimas SK, Laliberte AM, Montandon G, Fehlings MG.

Nature. 2018 Oct;562(7727):419-422. doi: 10.1038/s41586-018-0595-z. Epub 2018 Oct 10.

PMID:
30305735
3.

Delayed decompression exacerbates ischemia-reperfusion injury in cervical compressive myelopathy.

Vidal PM, Karadimas SK, Ulndreaj A, Laliberte AM, Tetreault L, Forner S, Wang J, Foltz WD, Fehlings MG.

JCI Insight. 2017 Jun 2;2(11). pii: 92512. doi: 10.1172/jci.insight.92512. eCollection 2017 Jun 2.

4.

Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.

Karadimas SK, Laliberte AM, Tetreault L, Chung YS, Arnold P, Foltz WD, Fehlings MG.

Sci Transl Med. 2015 Dec 2;7(316):316ra194. doi: 10.1126/scitranslmed.aac6524.

PMID:
26631633
5.

Riluzole promotes motor and respiratory recovery associated with enhanced neuronal survival and function following high cervical spinal hemisection.

Satkunendrarajah K, Nassiri F, Karadimas SK, Lip A, Yao G, Fehlings MG.

Exp Neurol. 2016 Feb;276:59-71. doi: 10.1016/j.expneurol.2015.09.011. Epub 2015 Sep 21.

6.

Degenerative Cervical Myelopathy: Epidemiology, Genetics, and Pathogenesis.

Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG.

Spine (Phila Pa 1976). 2015 Jun 15;40(12):E675-93. doi: 10.1097/BRS.0000000000000913. Review.

PMID:
25839387
7.

Bilateral contusion-compression model of incomplete traumatic cervical spinal cord injury.

Forgione N, Karadimas SK, Foltz WD, Satkunendrarajah K, Lip A, Fehlings MG.

J Neurotrauma. 2014 Nov 1;31(21):1776-88. doi: 10.1089/neu.2014.3388. Epub 2014 Sep 12.

8.

Delayed administration of a bio-engineered zinc-finger VEGF-A gene therapy is neuroprotective and attenuates allodynia following traumatic spinal cord injury.

Figley SA, Liu Y, Karadimas SK, Satkunendrarajah K, Fettes P, Spratt SK, Lee G, Ando D, Surosky R, Giedlin M, Fehlings MG.

PLoS One. 2014 May 20;9(5):e96137. doi: 10.1371/journal.pone.0096137. eCollection 2014.

9.

Pathobiology of cervical spondylotic myelopathy.

Karadimas SK, Gatzounis G, Fehlings MG.

Eur Spine J. 2015 Apr;24 Suppl 2:132-8. doi: 10.1007/s00586-014-3264-4. Epub 2014 Mar 14. Review.

PMID:
24626958
10.

Synergistic effects of self-assembling peptide and neural stem/progenitor cells to promote tissue repair and forelimb functional recovery in cervical spinal cord injury.

Iwasaki M, Wilcox JT, Nishimura Y, Zweckberger K, Suzuki H, Wang J, Liu Y, Karadimas SK, Fehlings MG.

Biomaterials. 2014 Mar;35(9):2617-29. doi: 10.1016/j.biomaterials.2013.12.019. Epub 2014 Jan 7.

PMID:
24406216
11.

Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy.

Moon ES, Karadimas SK, Yu WR, Austin JW, Fehlings MG.

Neurobiol Dis. 2014 Feb;62:394-406. doi: 10.1016/j.nbd.2013.10.020. Epub 2013 Oct 29.

PMID:
24184328
12.

Pathophysiology and natural history of cervical spondylotic myelopathy.

Karadimas SK, Erwin WM, Ely CG, Dettori JR, Fehlings MG.

Spine (Phila Pa 1976). 2013 Oct 15;38(22 Suppl 1):S21-36. doi: 10.1097/BRS.0b013e3182a7f2c3. Review.

PMID:
23963004
13.

Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial.

Fehlings MG, Wilson JR, Karadimas SK, Arnold PM, Kopjar B.

Spine (Phila Pa 1976). 2013 Oct 15;38(22 Suppl 1):S68-75. doi: 10.1097/BRS.0b013e3182a7e9b0. Review.

PMID:
23962993
14.

A novel experimental model of cervical spondylotic myelopathy (CSM) to facilitate translational research.

Karadimas SK, Moon ES, Yu WR, Satkunendrarajah K, Kallitsis JK, Gatzounis G, Fehlings MG.

Neurobiol Dis. 2013 Jun;54:43-58. doi: 10.1016/j.nbd.2013.02.013. Epub 2013 Mar 4.

PMID:
23466695
15.

Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder.

Kalsi-Ryan S, Karadimas SK, Fehlings MG.

Neuroscientist. 2013 Aug;19(4):409-21. doi: 10.1177/1073858412467377. Epub 2012 Nov 30. Review.

PMID:
23204243
16.

Immunohistochemical profile of NF-κB/p50, NF-κB/p65, MMP-9, MMP-2, and u-PA in experimental cervical spondylotic myelopathy.

Karadimas SK, Klironomos G, Papachristou DJ, Papanikolaou S, Papadaki E, Gatzounis G.

Spine (Phila Pa 1976). 2013 Jan 1;38(1):4-10. doi: 10.1097/BRS.0b013e318261ea6f.

PMID:
22673181
17.

The role of oligodendrocytes in the molecular pathobiology and potential molecular treatment of cervical spondylotic myelopathy.

Karadimas SK, Gialeli CH, Klironomos G, Tzanakakis GN, Panagiotopoulos E, Karamanos NK, Gatzounis G.

Curr Med Chem. 2010;17(11):1048-58. Review.

PMID:
20156160

Supplemental Content

Loading ...
Support Center